Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clear-Brain
NCT06421532Phase 2Enrolling by invitation
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in cerebral amyloid angiopathy (CAA) (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Morning amyloid-beta 40 and 42 levels in cerebrospinal fluid at 3 months. Started Mar 2025; status: enrolling by invitation.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NCT06421532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421532.